OA11836A - Controlled release formulation for treating COPD. - Google Patents

Controlled release formulation for treating COPD. Download PDF

Info

Publication number: OA11836A
Authority: OA; OAPI
Prior art keywords: formulation; inhibitor; daims; pde4; amount
Prior art date: 1999-02-23

Application number

OA1200100217A

Other languages

English (en)

Inventor

Patrick G Faulkner

Jaime J Lucca

Thomas J Wrzosek

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-23

Filing date

2000-02-22

Publication date

2005-08-22

2000-02-22 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2005-08-22 Publication of OA11836A publication Critical patent/OA11836A/en

Links

239000000203 mixture Substances 0.000 title claims abstract description 85
238000009472 formulation Methods 0.000 title claims abstract description 70
238000013270 controlled release Methods 0.000 title claims abstract description 33
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 26
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 25
229920002125 Sokalan® Polymers 0.000 claims description 37
230000000694 effects Effects 0.000 claims description 27
238000004090 dissolution Methods 0.000 claims description 26
239000003112 inhibitor Substances 0.000 claims description 24
238000000034 method Methods 0.000 claims description 20
239000000546 pharmaceutical excipient Substances 0.000 claims description 19
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 15
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 claims description 15
229950005741 rolipram Drugs 0.000 claims description 15
101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 claims description 14
238000002156 mixing Methods 0.000 claims description 13
230000008569 process Effects 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
230000002401 inhibitory effect Effects 0.000 claims description 8
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 claims description 7
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims description 7
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims description 7
230000002411 adverse Effects 0.000 claims description 7
206010061218 Inflammation Diseases 0.000 claims description 6
235000019700 dicalcium phosphate Nutrition 0.000 claims description 6
229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims description 6
230000004054 inflammatory process Effects 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 6
230000001225 therapeutic effect Effects 0.000 claims description 6
JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
230000003197 catalytic effect Effects 0.000 claims description 5
HJORMJIFDVBMOB-LBPRGKRZSA-N (-)-rolipram Chemical compound COC1=CC=C([C@H]2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-LBPRGKRZSA-N 0.000 claims description 4
QMYRXIWINUJUNY-UHFFFAOYSA-N 4-[6,7-diethoxy-2,3-bis(hydroxymethyl)naphthalen-1-yl]-1-(2-methoxyethyl)pyridin-2-one Chemical compound C=12C=C(OCC)C(OCC)=CC2=CC(CO)=C(CO)C=1C=1C=CN(CCOC)C(=O)C=1 QMYRXIWINUJUNY-UHFFFAOYSA-N 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 4
KYFWUBJMTHVBIF-QFIPXVFZSA-N dsstox_cid_27248 Chemical compound N([C@@H]1N=C(C=2C=3N(C1=O)CCC=3C=C(C=2)C)C=1C=CC=CC=1)C(=O)C1=CC=NC=C1 KYFWUBJMTHVBIF-QFIPXVFZSA-N 0.000 claims description 4
150000002148 esters Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
FSDOTMQXIKBFKJ-UHFFFAOYSA-N n-(2,5-dichloropyridin-3-yl)-8-methoxyquinoline-5-carboxamide Chemical compound C12=CC=CN=C2C(OC)=CC=C1C(=O)NC1=CC(Cl)=CN=C1Cl FSDOTMQXIKBFKJ-UHFFFAOYSA-N 0.000 claims description 4
229920000642 polymer Polymers 0.000 claims description 4
229940002612 prodrug Drugs 0.000 claims description 4
239000000651 prodrug Substances 0.000 claims description 4
MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims description 4
239000000758 substrate Substances 0.000 claims description 4
239000003456 ion exchange resin Substances 0.000 claims description 3
229920003303 ion-exchange polymer Polymers 0.000 claims description 3
230000003204 osmotic effect Effects 0.000 claims description 3
-1 V-l 1294A Chemical compound 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 3
229960002586 roflumilast Drugs 0.000 claims 3
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 2
KLPQJJKXRIDASJ-UHFFFAOYSA-N 3-[(3-cyclopentyloxy-4-methoxyphenyl)methyl]-N-ethyl-8-propan-2-yl-7H-purin-6-imine Chemical compound CCN=C1C2=C(N=C(N2)C(C)C)N(C=N1)CC3=CC(=C(C=C3)OC)OC4CCCC4 KLPQJJKXRIDASJ-UHFFFAOYSA-N 0.000 claims 2
DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical group C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 claims 2
AFQWGLBHIFKZOW-UHFFFAOYSA-N 1-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)cyclohexane-1-carboxylic acid Chemical compound COC1=CC=C(C2CCC(CC2)(C#N)C(O)=O)C=C1OC1CCCC1 AFQWGLBHIFKZOW-UHFFFAOYSA-N 0.000 claims 1
239000003957 anion exchange resin Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
208000006673 asthma Diseases 0.000 abstract description 4
238000013268 sustained release Methods 0.000 abstract description 4
239000012730 sustained-release form Substances 0.000 abstract description 4
208000027866 inflammatory disease Diseases 0.000 abstract description 2
239000003814 drug Substances 0.000 description 36
229940079593 drug Drugs 0.000 description 34
239000000306 component Substances 0.000 description 32
150000001875 compounds Chemical class 0.000 description 17
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 12
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
229960001631 carbomer Drugs 0.000 description 10
230000004044 response Effects 0.000 description 9
108010044467 Isoenzymes Proteins 0.000 description 8
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
239000008101 lactose Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000013461 design Methods 0.000 description 5
238000011282 treatment Methods 0.000 description 5
239000011324 bead Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000008213 purified water Substances 0.000 description 4
208000023504 respiratory system disease Diseases 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
208000030507 AIDS Diseases 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
206010040070 Septic Shock Diseases 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
238000013459 approach Methods 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
230000036765 blood level Effects 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
201000006549 dyspepsia Diseases 0.000 description 3
208000024798 heartburn Diseases 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000008693 nausea Effects 0.000 description 3
208000024981 pyrosis Diseases 0.000 description 3
239000000725 suspension Substances 0.000 description 3
CFBUZOUXXHZCFB-UHFFFAOYSA-N 4-cyano-4-(3-cyclopentyloxy-4-methoxyphenyl)-1-cyclohexanecarboxylic acid Chemical compound COC1=CC=C(C2(CCC(CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-UHFFFAOYSA-N 0.000 description 2
206010001513 AIDS related complex Diseases 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
206010017533 Fungal infection Diseases 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
208000005314 Multi-Infarct Dementia Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
201000004810 Vascular dementia Diseases 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
229940125388 beta agonist Drugs 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
150000001735 carboxylic acids Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
239000003172 expectorant agent Substances 0.000 description 2
238000013401 experimental design Methods 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000003199 leukotriene receptor blocking agent Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
230000036515 potency Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000000506 psychotropic effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
230000004797 therapeutic response Effects 0.000 description 2
FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
HJPRDDKCXVCFOH-UHFFFAOYSA-N 1,3-dibutyl-7-(2-oxopropyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CC(C)=O)C=N2 HJPRDDKCXVCFOH-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
MRHCSNNEUHXNIC-UHFFFAOYSA-N 9-benzylpurin-6-amine Chemical compound C1=NC=2C(N)=NC=NC=2N1CC1=CC=CC=C1 MRHCSNNEUHXNIC-UHFFFAOYSA-N 0.000 description 1
239000011475 Accrington brick Substances 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
206010060933 Adverse event Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
206010014824 Endotoxic shock Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
201000005569 Gout Diseases 0.000 description 1
206010018634 Gouty Arthritis Diseases 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
241000282337 Nasua nasua Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000206608 Pyropia tenera Species 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
241000746181 Therates Species 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
238000007792 addition Methods 0.000 description 1
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
229940086737 allyl sucrose Drugs 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000000954 anitussive effect Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
239000003434 antitussive agent Substances 0.000 description 1
229940124584 antitussives Drugs 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940049638 carbomer homopolymer type c Drugs 0.000 description 1
229940082484 carbomer-934 Drugs 0.000 description 1
229940043234 carbomer-940 Drugs 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000019771 cognition Effects 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
239000000599 controlled substance Substances 0.000 description 1
239000008358 core component Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
229950004687 denbufylline Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000916 dilatatory effect Effects 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003602 elastase inhibitor Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000003419 expectorant effect Effects 0.000 description 1
229940066493 expectorants Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
229920006158 high molecular weight polymer Polymers 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
229940124622 immune-modulator drug Drugs 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
208000011379 keloid formation Diseases 0.000 description 1
102000003835 leukotriene receptors Human genes 0.000 description 1
108090000146 leukotriene receptors Proteins 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
229920001684 low density polyethylene Polymers 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
230000000510 mucolytic effect Effects 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000000133 nasal decongestant Substances 0.000 description 1
230000008518 non respiratory effect Effects 0.000 description 1
239000012740 non-selective inhibitor Substances 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000007170 pathology Effects 0.000 description 1
WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
238000010517 secondary reaction Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
230000008685 targeting Effects 0.000 description 1
230000009772 tissue formation Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

OA1200100217A 1999-02-23 2000-02-22 Controlled release formulation for treating COPD. OA11836A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12129199P	1999-02-23	1999-02-23

Publications (1)

Publication Number	Publication Date
OA11836A true OA11836A (en)	2005-08-22

Family

ID=22395738

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100217A OA11836A (en)	1999-02-23	2000-02-22	Controlled release formulation for treating COPD.

Country Status (29)

Country	Link
US (1)	US20030211152A1 (id)
EP (1)	EP1154758A4 (id)
JP (1)	JP2002537320A (id)
KR (1)	KR20010112279A (id)
CN (1)	CN1195496C (id)
AR (1)	AR028986A1 (id)
AU (1)	AU3501500A (id)
BG (1)	BG105905A (id)
BR (1)	BR0008382A (id)
CA (1)	CA2366747A1 (id)
CO (1)	CO5150233A1 (id)
CZ (1)	CZ20013025A3 (id)
EA (1)	EA200100906A1 (id)
HK (1)	HK1043045A1 (id)
HU (1)	HUP0200134A3 (id)
ID (1)	ID29792A (id)
IL (1)	IL144603A0 (id)
MA (1)	MA25386A1 (id)
MY (1)	MY121142A (id)
NO (1)	NO20014049L (id)
NZ (1)	NZ527716A (id)
OA (1)	OA11836A (id)
PE (1)	PE20001496A1 (id)
PL (1)	PL350287A1 (id)
SK (1)	SK12072001A3 (id)
TR (1)	TR200102448T2 (id)
TW (1)	TWI224013B (id)
WO (1)	WO2000050011A1 (id)
ZA (1)	ZA200106803B (id)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003513038A (ja) *	1999-10-29	2003-04-08	スミスクライン・ビーチャム・コーポレイション	ホスホジエステラーゼ４阻害剤の投与法
EP1389468A4 (en) *	2001-05-23	2007-01-10	Tanabe Seiyaku Co	COMPOSITIONS FOR PROMOTING BONE FRACTURE HEALING
CN1537018A (zh) *	2001-05-23	2004-10-13	田边制药株式会社	一种用于软骨疾病再生治疗的组合物
JP2005505570A (ja) *	2001-09-19	2005-02-24	アルタナ　ファルマ　アクチエンゲゼルシャフト	Ｐｄｅ阻害剤及びロイコトリエン受容体拮抗物質の複合薬
MY140561A (en)	2002-02-20	2009-12-31	Nycomed Gmbh	Dosage form containing pde 4 inhibitor as active ingredient
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
WO2005030178A1 (en) *	2003-09-30	2005-04-07	Lupin Ltd.	Extended release formulation of beta-lactam antibiotics
PE20060272A1 (es)	2004-05-24	2006-05-22	Glaxo Group Ltd	(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
UA93608C2 (ru) *	2004-08-13	2011-02-25	Берингер Ингельхайм Интернациональ Гмбх	композициЯ таблетки пролонгированного высвобождения, которая содержит прамипексол или его фармацевтически приемлемую соль, СПОСОБ EE ИЗГОТОВЛЕНИЯ И EE ПРИМЕНЕНИЕ
GB0511066D0 (en) *	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
CN109908139B (zh) *	2018-12-28	2022-02-22	南京市儿童医院	西洛司特在制备用于治疗急性肾损伤相关病症的药物中的用途
BR112021013675A2 (pt) *	2019-01-15	2021-09-14	UNION therapeutics A/S	Formulações de comprimido de liberação modificada que contêm inibidores de fosfodiesterase
GB202306662D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Dosage regimen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE636568A (id) *	1961-01-31
IL78017A (en) *	1986-03-03	1989-06-30	Yissum Res Dev Co	Sustained release tablets of theophylline
US5286494A (en) *	1986-07-02	1994-02-15	Schering Aktiengesellschaft	Medicinal agents with sustained action
US5552438A (en) *	1992-04-02	1996-09-03	Smithkline Beecham Corporation	Compounds useful for treating allergic and inflammatory diseases
GB9222253D0 (en) *	1992-10-23	1992-12-09	Celltech Ltd	Chemical compounds
US5672622A (en) *	1994-04-21	1997-09-30	Berlex Laboratories, Inc.	Treatment of multiple sclerosis
US5998428A (en) *	1995-05-31	1999-12-07	Smithkline Beecham Corporation	Compounds and methods for treating PDE IV-related diseases
US6210710B1 (en) *	1997-04-28	2001-04-03	Hercules Incorporated	Sustained release polymer blend for pharmaceutical applications
US5840329A (en) *	1997-05-15	1998-11-24	Bioadvances Llc	Pulsatile drug delivery system
AR035987A1 (es) *	1999-03-01	2004-08-04	Smithkline Beecham Corp	Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio

2000
- 2000-02-21 MY MYPI20000615A patent/MY121142A/en unknown
- 2000-02-21 AR ARP000100730A patent/AR028986A1/es not_active Application Discontinuation
- 2000-02-22 OA OA1200100217A patent/OA11836A/en unknown
- 2000-02-22 ID IDW00200101812A patent/ID29792A/id unknown
- 2000-02-22 EP EP00913600A patent/EP1154758A4/en not_active Withdrawn
- 2000-02-22 AU AU35015/00A patent/AU3501500A/en not_active Abandoned
- 2000-02-22 TR TR2001/02448T patent/TR200102448T2/xx unknown
- 2000-02-22 PE PE2000000135A patent/PE20001496A1/es not_active Application Discontinuation
- 2000-02-22 IL IL14460300A patent/IL144603A0/xx unknown
- 2000-02-22 CN CNB008042098A patent/CN1195496C/zh not_active Expired - Fee Related
- 2000-02-22 HK HK02102791.5A patent/HK1043045A1/zh unknown
- 2000-02-22 HU HU0200134A patent/HUP0200134A3/hu unknown
- 2000-02-22 PL PL00350287A patent/PL350287A1/xx not_active Application Discontinuation
- 2000-02-22 EA EA200100906A patent/EA200100906A1/ru unknown
- 2000-02-22 SK SK1207-2001A patent/SK12072001A3/sk unknown
- 2000-02-22 CA CA002366747A patent/CA2366747A1/en not_active Abandoned
- 2000-02-22 WO PCT/US2000/004713 patent/WO2000050011A1/en not_active Ceased
- 2000-02-22 KR KR1020017010666A patent/KR20010112279A/ko not_active Ceased
- 2000-02-22 CZ CZ20013025A patent/CZ20013025A3/cs unknown
- 2000-02-22 BR BR0008382-8A patent/BR0008382A/pt not_active IP Right Cessation
- 2000-02-22 NZ NZ527716A patent/NZ527716A/en unknown
- 2000-02-22 JP JP2000600623A patent/JP2002537320A/ja not_active Withdrawn
- 2000-02-23 CO CO00012706A patent/CO5150233A1/es unknown
- 2000-03-15 TW TW089103003A patent/TWI224013B/zh not_active IP Right Cessation
2001
- 2001-08-17 ZA ZA200106803A patent/ZA200106803B/en unknown
- 2001-08-20 NO NO20014049A patent/NO20014049L/no unknown
- 2001-08-23 MA MA26303A patent/MA25386A1/fr unknown
- 2001-09-14 BG BG105905A patent/BG105905A/bg unknown
2003
- 2003-06-12 US US10/460,613 patent/US20030211152A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030211152A1 (en)	2003-11-13
PE20001496A1 (es)	2001-02-08
ID29792A (id)	2001-10-11
MY121142A (en)	2005-12-30
PL350287A1 (en)	2002-12-02
HK1043045A1 (zh)	2002-09-06
HUP0200134A3 (en)	2003-03-28
NO20014049L (no)	2001-10-22
TR200102448T2 (tr)	2003-03-21
EP1154758A4 (en)	2007-09-05
NO20014049D0 (no)	2001-08-20
IL144603A0 (en)	2002-05-23
WO2000050011A1 (en)	2000-08-31
CZ20013025A3 (cs)	2002-07-17
TWI224013B (en)	2004-11-21
AU3501500A (en)	2000-09-14
NZ527716A (en)	2005-03-24
BR0008382A (pt)	2002-02-05
AR028986A1 (es)	2003-06-04
JP2002537320A (ja)	2002-11-05
EA200100906A1 (ru)	2002-02-28
MA25386A1 (fr)	2002-04-01
BG105905A (bg)	2002-04-30
SK12072001A3 (sk)	2002-01-07
CA2366747A1 (en)	2000-08-31
ZA200106803B (en)	2002-08-19
HUP0200134A2 (hu)	2002-05-29
CN1347314A (zh)	2002-05-01
KR20010112279A (ko)	2001-12-20
CO5150233A1 (es)	2002-04-29
EP1154758A1 (en)	2001-11-21
CN1195496C (zh)	2005-04-06

Publication	Publication Date	Title
US4753801A (en)	1988-06-28	Sustained release tablets
EP0264187B1 (en)	1990-11-22	Pharmaceutical composition containing ibuprofen and aluminium hydroxide
OA11836A (en)	2005-08-22	Controlled release formulation for treating COPD.
US20030044462A1 (en)	2003-03-06	Sustained release tablets containing bupropion hydrochloride
US20030175338A1 (en)	2003-09-18	Formulations of atorvastatin stabilized with alkali metal additions
NZ515780A (en)	2004-06-25	Levodopa / carbidopa / entacapone pharmaceutical preparation
JP2007314578A (ja)	2007-12-06	経口投与後のトリメタジジンの持続性放出を可能とするマトリックス錠
SK138099A3 (en)	2000-04-10	Extended release formulations of erythromycin derivatives
US20130245082A1 (en)	2013-09-19	Bioavailable compositions of metaxolone comprising nonvolatile liquids and processes for producing the same
JPS6241646B2 (id)	1987-09-03
US20120141586A1 (en)	2012-06-07	Thrombin receptor antagonist and clopidogrel fixed dose tablet
US20050169991A1 (en)	2005-08-04	Sustained release torsemide dosage forms
KR20020050249A (ko)	2002-06-26	포스포디에스테라제 4 억제제의 투여 방법
SK281193B6 (sk)	2001-01-18	Tableta so zlepšenou biodostupnosťou účinnej látky, kyseliny klodrónovej, spôsob jej výroby a použitie mikrokryštalickej celulózy
US6713509B1 (en)	2004-03-30	Controlled release formulation for treating COPD
KR20030019620A (ko)	2003-03-06	Ｃｏｐｄ와 관련된 증상 악화의 감소 방법
JP2006520770A (ja)	2006-09-14	フィブレートを含有する錠剤の形の製薬組成物の製造方法、および該方法に従って得られた錠剤
AU2004201503A1 (en)	2004-05-06	Controlled Release Formulation for Treating COPD
MXPA01008523A (en)	2002-05-09	Controlled release formulation for treating copd
EP3731829B1 (en)	2024-07-17	Tablet compositions of fesoterodine fumarate
JP2022517616A (ja)	2022-03-09	ネフォパムおよびアセトアミノフェンを含む薬学的組成物の製造方法、およびそれによって得られる薬学的組成物
RU2354358C1 (ru)	2009-05-10	Твердая лекарственная форма матричного типа, обладающая противовоспалительной, анальгезирующей, жаропонижающей активностью, с пролонгированным высвобождением, и способ ее получения
HK1071847A1 (zh)	2005-08-05	具有延長的活性成分釋放的劑型
HK1184690A (en)	2014-01-30	Bioavailable solid dosage forms of metaxalone
HK1071847B (en)	2010-04-09	Dosage forms having prolonged active ingredient release